Behavioral and Neurochemical Changes in Mesostriatal Dopaminergic Regions of the Rat After Chronic Administration of the Cannabinoid Receptor Agonist WIN55,212-2

Overview

Journal Int J Neuropsychopharmacol

Publisher Oxford University Press

Specialty Psychiatry

Date 2014 Dec 19

PMID 25522428

Citations 5

Authors

Eleni Fanarioti

Maria Mavrikaki

George Panagis

Ada Mitsacos

George G Nomikos

Panagiotis Giompres

Affiliations

Soon will be listed here.

Abstract

Background: The endocannabinoid system interacts extensively with other neurotransmitter systems and has been implicated in a variety of functions, including regulation of basal ganglia circuits and motor behavior. The present study examined the effects of repeated administration of the nonselective cannabinoid receptor 1 agonist WIN55,212-2 on locomotor activity and on binding and mRNA levels of dopamine receptors and transporters and GABAA receptors in mesostriatal dopaminergic regions of the rat.

Methods: Rats received systemic injections of WIN55,212-2 (0, 0.1, 0.3, or 1mg/kg, intraperitoneally) for 20 consecutive days. Locomotor activity was measured on days 1, 10, and 20. Following the last measurement, rats were euthanized and prepared for in vitro binding and in situ hybridization experiments.

Results: Acutely, 0.3 and 1mg/kg of WIN55,212-2 produced hypolocomotion, which was sustained for the next 2 measurements, compared to vehicle. Repeated administration of WIN55,212-2 decreased the mRNA levels of the D2 autoreceptors in substantia nigra and ventral tegmental area and increased D1 receptor mRNA and binding in nucleus accumbens. Furthermore, both dopamine receptor and transporter binding and mRNA levels were decreased in substantia nigra. Moreover, repeated administration of WIN55,212-2 decreased GABAA receptor binding levels in dorsal striatum and substantia nigra.

Conclusions: Our data indicate that chronic WIN55,212-2 administration results in sustained effects on locomotor activity, similar to those observed after acute administration, and modulates the dopaminergic and GABAergic systems in a region-, dose-, and neurotransmitter-selective manner.

Citing Articles

Fine-tuning of dopamine receptor signaling with aripiprazole counteracts ketamine's dissociative action, but not its antidepressant effect.

Nakatsuka D, Suwa T, Deguchi Y, Fujita Y, Tashima R, Ohnami S Transl Psychiatry. 2025; 15(1):77.

PMID: 40057507 PMC: 11890785. DOI: 10.1038/s41398-025-03284-9.

Differential cannabinoid-like effects and pharmacokinetics of ADB-BICA, ADB-BINACA, ADB-4en-PINACA and MDMB-4en-PINACA in mice: A comparative study.

Zhou F, Wang X, Tan S, Shi Y, Xie B, Xiang P Addict Biol. 2024; 29(2):e13372.

PMID: 38380735 PMC: 10898835. DOI: 10.1111/adb.13372.

Evidence from Human Studies for Utilising Cannabinoids for the Treatment of Substance-Use Disorders: A Scoping Review with a Systematic Approach.

Gharbi K, Bonomo Y, Hallinan C Int J Environ Res Public Health. 2023; 20(5).

PMID: 36901098 PMC: 10001982. DOI: 10.3390/ijerph20054087.

Early life stress influences basal ganglia dopamine receptors and novel object recognition of adolescent and adult rats.

Sinani A, Vassi A, Tsotsokou G, Nikolakopoulou M, Kouvelas E, Mitsacos A IBRO Neurosci Rep. 2022; 12:342-354.

PMID: 35572456 PMC: 9092503. DOI: 10.1016/j.ibneur.2022.04.008.

Chronic cannabinoid exposure produces tolerance to the dopamine releasing effects of WIN 55,212-2 and heroin in adult male rats.

Gomez D, Everett T, Hamilton L, Ranganath A, Cheer J, Oleson E Neuropharmacology. 2020; 182:108374.

PMID: 33115642 PMC: 7836093. DOI: 10.1016/j.neuropharm.2020.108374.

References

Manzoni O, Bockaert J . Cannabinoids inhibit GABAergic synaptic transmission in mice nucleus accumbens. Eur J Pharmacol. 2001; 412(2):R3-5. DOI: 10.1016/s0014-2999(01)00723-3. View

Kearn C, Greenberg M, DiCamelli R, Kurzawa K, Hillard C . Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. J Neurochem. 1999; 72(6):2379-87. DOI: 10.1046/j.1471-4159.1999.0722379.x. View

Giannakopoulou D, Daguin-Nerriere V, Mitsacos A, Kouvelas E, Neveu I, Giompres P . Ectopic expression of TrKA in the adult rat basal ganglia induces both nerve growth factor-dependent and -independent neuronal responses. J Neurosci Res. 2012; 90(8):1507-21. DOI: 10.1002/jnr.23031. View

Pistis M, Ferraro L, Pira L, Flore G, Tanganelli S, Gessa G . Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res. 2002; 948(1-2):155-8. DOI: 10.1016/s0006-8993(02)03055-x. View

Zhou Q, Grandy D, Thambi L, Kushner J, Van Tol H, Cone R . Cloning and expression of human and rat D1 dopamine receptors. Nature. 1990; 347(6288):76-80. DOI: 10.1038/347076a0. View

Morera-Herreras T, Ruiz-Ortega J, Gomez-Urquijo S, Ugedo L . Involvement of subthalamic nucleus in the stimulatory effect of Delta(9)-tetrahydrocannabinol on dopaminergic neurons. Neuroscience. 2008; 151(3):817-23. DOI: 10.1016/j.neuroscience.2007.11.016. View

Usiello A, Baik J, Rouge-Pont F, Picetti R, Dierich A, Lemeur M . Distinct functions of the two isoforms of dopamine D2 receptors. Nature. 2000; 408(6809):199-203. DOI: 10.1038/35041572. View

Laviolette S, Lauzon N, Bishop S, Sun N, Tan H . Dopamine signaling through D1-like versus D2-like receptors in the nucleus accumbens core versus shell differentially modulates nicotine reward sensitivity. J Neurosci. 2008; 28(32):8025-33. PMC: 6670771. DOI: 10.1523/JNEUROSCI.1371-08.2008. View

Starke K, Gothert M, Kilbinger H . Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev. 1989; 69(3):864-989. DOI: 10.1152/physrev.1989.69.3.864. View

10.

Giros B, Sokoloff P, Martres M, Riou J, Emorine L, Schwartz J . Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature. 1989; 342(6252):923-6. DOI: 10.1038/342923a0. View

11.

Maresz K, Pryce G, Ponomarev E, Marsicano G, Croxford J, Shriver L . Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med. 2007; 13(4):492-7. DOI: 10.1038/nm1561. View

12.

Khan Z, Mrzljak L, Gutierrez A, de la Calle A, Goldman-Rakic P . Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc Natl Acad Sci U S A. 1998; 95(13):7731-6. PMC: 22740. DOI: 10.1073/pnas.95.13.7731. View

13.

Arnold J, Topple A, Hunt G, McGregor I . Effects of pre-exposure and co-administration of the cannabinoid receptor agonist CP 55,940 on behavioral sensitization to cocaine. Eur J Pharmacol. 1998; 354(1):9-16. DOI: 10.1016/s0014-2999(98)00433-6. View

14.

Hashimotodani Y, Ohno-Shosaku T, Kano M . Endocannabinoids and synaptic function in the CNS. Neuroscientist. 2007; 13(2):127-37. DOI: 10.1177/1073858406296716. View

15.

Polissidis A, Chouliara O, Galanopoulos A, Rentesi G, Dosi M, Hyphantis T . Individual differences in the effects of cannabinoids on motor activity, dopaminergic activity and DARPP-32 phosphorylation in distinct regions of the brain. Int J Neuropsychopharmacol. 2009; 13(9):1175-91. DOI: 10.1017/S1461145709991003. View

16.

Ginovart N, Tournier B, Moulin-Sallanon M, Steimer T, Ibanez V, Millet P . Chronic Δ⁹-tetrahydrocannabinol exposure induces a sensitization of dopamine D₂/₃ receptors in the mesoaccumbens and nigrostriatal systems. Neuropsychopharmacology. 2012; 37(11):2355-67. PMC: 3442351. DOI: 10.1038/npp.2012.91. View

17.

Cragg S, Greenfield S . Differential autoreceptor control of somatodendritic and axon terminal dopamine release in substantia nigra, ventral tegmental area, and striatum. J Neurosci. 1997; 17(15):5738-46. PMC: 6573186. View

18.

Matsuda L, Bonner T, Lolait S . Localization of cannabinoid receptor mRNA in rat brain. J Comp Neurol. 1993; 327(4):535-50. DOI: 10.1002/cne.903270406. View

19.

Mercuri N, Calabresi P, Bernardi G . The mechanism of amphetamine-induced inhibition of rat substantia nigra compacta neurones investigated with intracellular recording in vitro. Br J Pharmacol. 1989; 98(1):127-34. PMC: 1854659. DOI: 10.1111/j.1476-5381.1989.tb16872.x. View

20.

Romero J, Seale G, Fernandez-Ruiz J, Walker J . Activational role of cannabinoids on movement. Eur J Pharmacol. 2000; 391(3):269-74. DOI: 10.1016/s0014-2999(00)00044-3. View